Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Research output: Journal contributionsJournal articlesResearchpeer-review

Authors

  • Werner Christian Neubauer
  • Monika Engelhardt
  • Armin König
  • Stefanie Hieke
  • Manfred Jung
  • Hartmut Bertz
  • Klaus Kümmerer
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number9
Pages (from-to)4029-4032
Number of pages4
DOIs
Publication statusPublished - 09.2010
Externally publishedYes

    Research areas

  • Chemistry - Adult, Aged, Antifungal Agents, Chromatography, High Pressure Liquid, Female, Hematologic Neoplasms, Humans, Male, Middle Aged, Mycoses, Prospective Studies, Triazoles

DOI